Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.46 |
| ▸ | CTSD | P07339 | 8/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8412199 | 0.85 | BACE1 (0.48) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL7560123 | 0.85 | BACE1 (0.49) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL13054159 | 0.85 | BACE1 (0.49) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL8411137 | 0.84 | BACE1 (0.48) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL7570323 | 0.83 | BACE1 (0.48) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL13407672 | 0.81 | BACE1 (0.56) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL7541503 | 0.81 | CTSD (0.47) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL7546165 | 0.81 | BACE1 (0.56) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL2969339 | 0.74 | BACE1 (0.49) | BACE1CTSDMCHR1CXCR3 | |
| SCHEMBL2969336 | 0.74 | BACE1 (0.49) | BACE1CTSDMCHR1CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885CTSD 13/4885MCHR1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.